How New Developments in Pharmacology Receptor Theory Are Changing (Our Understanding Of) Hypertension Therapy

Overview

Journal Am J Hypertens

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2023 Dec 27

PMID 38150382

Authors

Stephanie W Watts

Raymond R Townsend

Richard R Neubig

Affiliations

Soon will be listed here.

Abstract

Background: Many hypertension therapeutics were developed prior to major advances in drug receptor theory. Moreover, newer drugs may take advantage of some of the newly understood modalities of receptor function.

Goal: The goal of this review is to provide an up-to-date summary of drug receptor theory. This is followed by a discussion of the drug classes recognized for treating hypertension to which new concepts in receptor theory apply.

Results: We raise ideas for mechanisms of potential new antihypertensive drugs and whether they may take advantage of new theories in drug-receptor interaction.

References

Funder J . Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens. 2001; 10(2):227-30. DOI: 10.1097/00041552-200103000-00011. View

Ali A, Palakkott A, Ashraf A, Zamel I, Baby B, Vijayan R . Positive Modulation of Angiotensin II Type 1 Receptor-Mediated Signaling by LVV-Hemorphin-7. Front Pharmacol. 2019; 10:1258. PMC: 6823245. DOI: 10.3389/fphar.2019.01258. View

Pang P, Butler J, Collins S, Cotter G, Davison B, Ezekowitz J . Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017; 38(30):2364-2373. PMC: 5837312. DOI: 10.1093/eurheartj/ehx196. View

Kaya A, Perry N, Gurevich V, Iverson T . Phosphorylation barcode-dependent signal bias of the dopamine D1 receptor. Proc Natl Acad Sci U S A. 2020; 117(25):14139-14149. PMC: 7321966. DOI: 10.1073/pnas.1918736117. View

Drucker D . Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001. View

Lefkowitz R . G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem. 1998; 273(30):18677-80. DOI: 10.1074/jbc.273.30.18677. View

Muntner P, Hardy S, Fine L, Jaeger B, Wozniak G, Levitan E . Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020; 324(12):1190-1200. PMC: 7489367. DOI: 10.1001/jama.2020.14545. View

Takezako T, Unal H, Karnik S, Node K . The non-biphenyl-tetrazole angiotensin AT receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT receptor. Br J Pharmacol. 2018; 175(12):2454-2469. PMC: 5980637. DOI: 10.1111/bph.14213. View

ARIUENS E, SIMONIS A . A MOLECULAR BASIS FOR DRUG ACTION. J Pharm Pharmacol. 1964; 16:137-57. DOI: 10.1111/j.2042-7158.1964.tb07437.x. View

10.

Luttrell L, Ferguson S, Daaka Y, Miller W, Maudsley S, Della Rocca G . Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999; 283(5402):655-61. DOI: 10.1126/science.283.5402.655. View

11.

BEYER K . Chlorothiazide. How the thiazides evolved as antihypertensive therapy. Hypertension. 1993; 22(3):388-91. DOI: 10.1161/01.hyp.22.3.388. View

12.

Clement D . Poor blood pressure control: what can we do?. J Hypertens. 2017; 35(7):1368-1370. DOI: 10.1097/HJH.0000000000001347. View

13.

Carey R, Moran A, Whelton P . Treatment of Hypertension: A Review. JAMA. 2022; 328(18):1849-1861. DOI: 10.1001/jama.2022.19590. View

14.

Song G, Yang D, Wang Y, de Graaf C, Zhou Q, Jiang S . Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature. 2017; 546(7657):312-315. DOI: 10.1038/nature22378. View

15.

Zanaty M, Seara F, Nakagawa P, Deng G, Mathieu N, Balapattabi K . β-Arrestin-Biased Agonist Targeting the Brain ATR (Angiotensin II Type 1 Receptor) Increases Aversion to Saline and Lowers Blood Pressure in Deoxycorticosterone Acetate-Salt Hypertension. Hypertension. 2020; 77(2):420-431. PMC: 7855825. DOI: 10.1161/HYPERTENSIONAHA.120.15793. View

16.

Kenakin T, Strachan R . PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?. Trends Pharmacol Sci. 2018; 39(8):748-765. DOI: 10.1016/j.tips.2018.05.001. View

17.

Maguire J . Evidence for biased agonists and antagonists at the endothelin receptors. Life Sci. 2016; 159:30-33. PMC: 5000545. DOI: 10.1016/j.lfs.2016.02.069. View

18.

DeVree B, Mahoney J, Velez-Ruiz G, Rasmussen S, Kuszak A, Edwald E . Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature. 2016; 535(7610):182-6. PMC: 5702553. DOI: 10.1038/nature18324. View

19.

Cerione R, CODINA J, Benovic J, Lefkowitz R, Birnbaumer L, Caron M . The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry. 1984; 23(20):4519-25. DOI: 10.1021/bi00315a003. View

20.

Goud A, Zhong J, Peters M, Brook R, Rajagopalan S . GLP-1 Agonists and Blood Pressure: A Review of the Evidence. Curr Hypertens Rep. 2016; 18(2):16. DOI: 10.1007/s11906-015-0621-6. View